Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies.

The 2026 program will dive into 3 parallel tracks, including: Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing. This is your opportunity to divide and conquer, where you can send different members across your team amongst 250+ LNP innovators, to ensure you gain a comprehensive understanding of the entire LNP development pipeline. From early formulation through to commercial-scale production, you can return to your company equipped with the insights needed to accelerate your LNP-mediated medicines.

Learn more in the official event guide here: https://ter.li/y6ipkw

Curated in collaboration with our Scientific Advisory Board, Annette Bak (AstraZeneca), Luis Brito (Beam Therapeutics), and Ching Kim Tye (Sanofi), this premier forum is designed to deliver LNP-specific networking and knowledge sharing. Our unmissable agenda highlights include:

• Attracting Investment & Acquisition Opportunities with Capstan Therapeutics, GV and Chiesi Global Rare Diseases
• Achieving Extrahepatic Targeting with LNPs with Alnylam, Servier and Novartis
• LNPs for Cell & Gene Therapy Delivery with Yoltech Therapeutics, Innorna and Corner Therapeutics
• Interactive LNP-Focused Workshop Day with Novo Nordisk, GSK and Editas Medicines
• Gain a Refresher on LNP Core Principles with Land Therapeutics, Beam Therapeutics and Arbor Biotechnology
• Formulating Thermostable LNPs with Eli Lilly & Co and AstraZeneca

Keen to find out more? Access our event overview on the LNP website here: https://ter.li/y6ipkw